Indivior
在场
Indivior 的所有者是 Reckitt Benckiser.
是其中之一......
Reckitt Benckiser 是一家在股票代码 RB (GB) 下上市的公司。
Reckitt Benckiser 在 10 个国家有直接业务。Reckitt Benckiser 拥有 12家子公司，其中包括 Indivior、Reckitt Benckiser ANZ 和 Reckitt Benckiser Arabia。
他们在：
高管
查看带有其 26 名主要高管的组织结构图
Indivior 搜索最多的简介
- Mark Crossley, Chief Executive Officer and Director (until May 202...
- Joe Ciaffoni, Independent Non-Executive Director (promoted in May ...
- Mark Stejbach, Non-Executive Director
高管在Indivior变化
- Robert Schriesheim, Independent Non-Executive Director, 已经离开公司 (新闻发布的2025三月5号).
- Peter Bains, Non-Executive Director, 已经离开公司 (新闻发布的2025三月5号).
- Mark Crossley, Chief Executive Officer and Director, 将于 20255月 退休 (新闻发布的2025二月28号).
高管在Reckitt Benckiser变化
- Kate Bloice 曾任 Head of Candidate Experience, 现任 Head of Talent and Learning, Finance, Information Technology and Development and Legal (新闻发布的2025三月19号).
- Kavan Stewart 曾任 Global Head of Mergers and Acquisitions, 现升职为 Vice President, Global Mergers and Acquisitions (新闻发布的2025一月5号).
- Stefan OschmannStefan Oschmann 将于20251月1作为 Non-Executive Director 加入公司 (新闻发布的2024十一月27号).
创建提醒
跟踪 Indivior 的高管变动
药店
Reckitt Benckiser 拥有 1,834 家竞争者，其中包括 Pfizer (美国(美洲))、Roche (瑞士) 和 Sanofi (法国)。
Popular M&A news in 药店
- Clario 已收购 NRx Pharmaceuticals (公布2025三月18号).
- Knight Therapeutics has announced the acquisition of Paladin Labs (公布2025三月12号).
- Jazz Pharmaceuticals 已收购 Chimerix (公布2025三月6号).
药店 行业的其他推荐联系人
消息
Indivior 的最新新闻稿
- Indivior | Indivior Announces Further Changes to Board of Directors
- Indivior | Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer
- Indivior | Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection
- Indivior | Indivior Announces FY and Q4 2024 Financial Results
- Indivior | Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024
- Indivior | Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024
- Indivior | Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
- Indivior | Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
- Indivior | Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month
- Indivior | Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month
- View more press releases Close
